Navigation Links
Enrollment Underway in CLARITY-AF Study to Compare Efficacy, Safety and Efficiency of Two Catheter Ablation Technologies
Date:7/8/2010

WATERLOO, Belgium, July 8, 2010 /PRNewswire/ -- Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announces that more than 10 patients have now been enrolled in the CLARITY-study ("CLARITY-AF"), comparing the efficacy, safety and efficiency of CARTO(R) 3 System guided radiofrequency ablation using the NAVISTAR(R) THERMOCOOL(R) catheter versus fluoroscopy guided radiofrequency ablation using the Pulmonary Vein Ablation catheter(R) (PVAC(R), Ablation Frontiers, Medtronic) in patients with paroxysmal atrial fibrillation (Clinicaltrials.gov ID NCT01116557) (http://www.clinicaltrials.gov/ct2/show/NCT01116557?term=PVAC&rank=1).

This prospective, multi-center, randomized (2:1), controlled, two-arm clinical study will enroll up to 350 patients at up to 15 sites throughout Europe. Patients in this study will be followed for one year after ablation. The study is intended to test the hypothesis that the NAVISTAR(R) THERMOCOOL(R) catheter using the CARTO(R) 3 System is superior to fluoroscopy-guided PVAC(R) for efficacy and safety and will demonstrate non-inferiority for efficiency comparing the NAVISTAR(R) THERMOCOOL(R) catheter used with the CARTO(R) 3 System to the PVAC(R) catheter. Interim results from the study will be disclosed after completion of the enrollment phase and the final results will be available at the end of the 1-year follow up period.

"The CLARITY-AF trial is the first multi-center randomized trial comparing atrial fibrillation ablation devices. This trial will compare the Medtronic PVAC(R) catheter to the Biosense Webster NAVISTAR(R) THERMOCOOL(R) catheter. Primary endpoints are freedom from any atrial fibrillation, atrial tachycardia, pulmonary vein stenosis and procedure time. Given the growing epidemic of atrial fibrillation, the results of this trial will guide optimal treatment in a large patient population" said Prof. Mattias Duytschaever from AZ St Jan Hospital in Bruges, Belgium, and principal investigator of the CLARITY-AF study.

With this study Biosense Webster shows its commitment to working towards a cure for atrial fibrillation and improving the quality of life of patients suffering from this disease. Atrial fibrillation is the most prevalent heart rhythm disorder, increasing in prevalence with age. Clinical data suggests that 20% of all strokes result from the illness, which often remains undiagnosed and which can increase the risk of a stroke fivefold.

"The CLARITY-AF study will rigorously evaluate the efficacy, safety and efficiency of the Biosense Webster NAVISTAR(R) THERMOCOOL(R) catheter with CARTO(R) 3 System guidance compared to the Medtronic Pulmonary Vein Ablation catheter(R) (PVAC(R)) with fluoroscopy for treating paroxysmal atrial fibrillation. With enrollment now started, we are confident that this scientific study will demonstrate objective results that will show the superiority of the NAVISTAR(R) THERMOCOOL(R) catheter system for treating atrial fibrillation", according to Shlomi Nachman, World Wide President of Biosense Webster. "We look forward to releasing the early results next year."

CARTO(R) 3 is the third generation of the CARTO(R) electro-anatomical mapping system, which brings the technology to an unprecedented level of performance. The system has been designed based on the feedback provided by several of the most prominent Key Opinion Leaders in the atrial fibrillation treatment arena. CARTO(R) 3 is built on the core magnetic based CARTO(R) proprietary technology, which has been recognized as the gold standard in its domain, with a special focus on increased performance, ease of use and Electrophysiology-lab efficiency.

The NAVISTAR(R) THERMOCOOL(R) catheter, manufactured by Biosense Webster, Inc. is one of the most widely adopted catheters for the treatment of atrial fibrillation in Europe, and the only ablation catheter approved by the U.S. Food and Drug Administration for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillation when used with CARTO(R) Navigation Systems.

According to data which appeared earlier this year in JAMA (Journal of American Medical Association, January 2010), patients with a common heart rhythm disorder, called atrial fibrillation, who were treated with catheter ablation using the NAVISTAR(R) THERMOCOOL(R) catheter, demonstrated significantly better outcomes at one year compared to those receiving drug therapy. In addition, the patients treated with catheter ablation reported markedly fewer symptoms and substantially improved quality of life.

About Biosense Webster, Inc.

Biosense Webster, Inc., a Johnson & Johnson company, pioneered electrophysiology diagnostic catheters more than 30 years ago and continues to lead the industry as an innovative provider of advanced diagnostic, therapeutic and mapping tools. As one of the leaders in navigation systems and ablation therapy, Biosense Webster, Inc.'s technology includes the largest installed base of navigation systems worldwide in leading hospitals and teaching institutions. With its proprietary products the company is changing the way electrophysiologists diagnose and treat arrhythmias.

The third party trademarks used herein are trademarks of their respective owners

    Contact:
    Ulrike Domany
    Director Public Affairs & Communication
    +43-1-36025-396
    +43-664-83-504-83
    udomany@its.jnj.com



'/>"/>
SOURCE Biosense Webster, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NeuroDerm Successfully Completes Enrollment and Dosing in a Phase 1 Clinical Study of ND0611 Dermal Patch for Parkinsons Disease
2. Logical Therapeutics Initiates Enrollment in New Gastrointestinal Safety Study in Osteoarthritis Patients
3. Cellectar Completes Enrollment in Phase I Clinical Trial of Lead Drug Candidate (131)I-CLR1404 for the Treatment of Solid Malignancies
4. GeoVax Labs, Inc. Begins Enrollment at Final Site for Preventative Vaccine; Next Step Is to Submit IND Application for Therapeutic Vaccine to FDA
5. Tenaxis Medical, Inc. Announces Completion of the Enrollment Phase of Their Pivotal Study
6. AstraZeneca Offers Online Enrollment and Additional Improvements to Patient Assistance Program
7. Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes
8. Dune Medical Completes Enrollment in MarginProbe(TM) Pivotal Trial for Real-Time Detection of Cancer During Breast Conservation Surgery
9. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
10. Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites
11. Helix BioPharma Corp. Completes Enrollment in Its Phase II Trial of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016 ... Companion Diagnostics in Personalized Medicine and Cancer Therapy. ... - High-Growth Diagnostic Testing Markets. - Key Diagnostic ... - Molecular Diagnostics in Genetic Testing. - ... Diagnostics Markets. - Over-the-Counter Diagnostic Products World Markets. ...
(Date:2/11/2016)... YORK , Feb. 11, 2016 ... instruments commonly used in laboratories. These may range from ... condensers. Laboratory glassware is made from borosilicate glass because ... Laboratory plasticware, on the other hand, started gaining popularity ... it was easier to replace glass with plastic in ...
(Date:2/11/2016)... , Feb. 11, 2016   Health 2.0 , ... new health technologies, announced today " 10 Year Global ... health tech over the past ten years.   ... a decade, Health 2.0 has served as the preeminent ... connected with thousands of technologies, companies, innovators, and patient-activists ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... 2016 , ... Itopia, a leader in cloud services automation ... Platform (CIP) into Cielo®, a discovery, migration and cloud orchestration engine. This integration ... and medium business (SMB) clients. , In recent years, BI and ...
(Date:2/12/2016)... ... February 12, 2016 , ... The Jones Agency, a family owned insurance company ... launching a cooperative charity drive with the Tarrant Area Food Bank in the hopes ... and families in need, the Tarrant County Food Bank offers hope and security to ...
(Date:2/12/2016)... ... 2016 , ... Donor Network West, the organ procurement organization that heals lives ... San Ramon Regional Medical Center. Under the collaboration, the first of its kind, specific ... a more certain time frame for donor families for the recovery of organs. ...
(Date:2/12/2016)... ... February 12, 2016 , ... Mediaplanet today announces ... The print component of “Revolutionizing Cancer Care” is distributed within the February 12 ... Seattle, with a circulation of approximately 250,000 copies and an estimated readership of ...
(Date:2/12/2016)... , ... February 12, 2016 , ... US Sport Camps ... Iowa. Legacy Golf Club, located in Norwalk, serves as the host site and directing ... Rob Randall. , “We have had successful camps in recent years around Des Moines ...
Breaking Medicine News(10 mins):